Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Doxazosin placebo Clear all
Completed Phase 1 Interventional

DOXAZOSIN FOR PTSD

NCT02308202
View directory record Official record
Conditions
PTSD
Interventions
doxazosin, Perindopril, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

NCT02989493
View directory record Official record
Conditions
Alcoholism
Interventions
Doxazosin, Placebo
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxazosin for Psychostimulant Dependence

NCT01371851
View directory record Official record
Conditions
Methamphetamine or Cocaine Dependence
Interventions
Doxazosin extended release
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

NCT01100021
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tamsulosin and avanafil, Doxazosin and avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Results available

The Efficacy of Doxazosin for Cocaine Users

NCT00880997
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

NCT01062945
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Placebo, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 25, 2026, 9:11 AM EDT
Not listed Phase 2 Interventional

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

NCT03339258
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin Mesylate, Extended Release, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

NCT00645034
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
placebo, sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
35 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Laguna Woods, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Doxazosin for Cocaine Dependence

NCT01145183
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 25, 2026, 9:11 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

NCT03415581
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Intranasal Oxycodone, Cue Session
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Early Phase 1 Interventional

Doxazosin an a1 Antagonist for Alcohol Dependence

NCT01437046
View directory record Official record
Conditions
Alcohol Dependence, Anxiety
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

NCT02500602
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Alcohol Use Disorders
Interventions
doxazosin, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Complementary Combination Therapy for Cocaine Dependence

NCT02538744
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Modafinil, cocaine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

NCT01730846
View directory record Official record
Conditions
Smoking
Interventions
Doxazosin 4mg/day, Placebo, Doxazosin 8mg/day
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 25, 2026, 9:11 AM EDT
Active, not recruiting Phase 2 Interventional

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

NCT04135846
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 9:11 AM EDT